The Pitch: HepaTx offers a new life for failing livers

HepaTx is developing novel cell therapies for liver failure that it said will restore liver function and help patients avoid a liver transplant. How it will make money The Palo Alto company will sell its cell therapy product to hepatologists and/or interventional radiologists for infusion into patients with liver failure, following approval by the FDA. Business it may disrupt It could reduce or eliminate the need for palliative care, wh ich addresses symptoms, but does not improve patient prognosis.…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news